Herbalife Nutrition Ltd. Q1 2026 Earnings Call Summary – Moby Strategic Evolution and Operational Performance
Achieved third consecutive quarter of volume growth and 7.8% net sales growth, driven by record performance in India following a GST rate reduction, which helped offset sales declines in North America and China.
Transitioning from personally curated to personally formulated nutrition, leveraging recent acquisitions to deliver individualized supplement outcomes at scale.
Executing a multiyear global packaging redesign to reinforce scientific credibility and simplify product navigation for distributors and customers.
Strengthened the capital structure through a $1.45 billion refinancing, extending maturities and unlocking approximately $45 million in annual cash interest savings.
Stabilized the distributor base with the Herbalife Premier League initiative, reversing 12 quarters of declines to achieve 13% new distributor growth on a two-year stack, though management noted this specific metric will be less relevant moving forward.
Integrating the Protocol digital platform as a central operating system to digitize distributor-customer engagement and scale health metric tracking.
Strategic Roadmap and Financial Outlook
Launching next-generation personalized nutritional supplements in 11 European markets in June and North America in July 2026.
Targeting a net leverage ratio below 2x by the end of 2026, with a long-term goal to reduce gross debt to $1.4 billion by 2028.
Anticipating full-year net sales growth in North America despite Q1 weather disruptions and revenue deferrals from shipments in transit.
Projecting a $20 million to $25 million headwind to full-year adjusted EBITDA due to the GST mismatch in India between collected and paid rates.
Expanding the Protocol beta program with a major feature release scheduled for the North America Extravaganza in July 2026.
Strategic Acquisitions and Market Risks
Completed the acquisition of Vionic’s personalized nutrition business for $55 million base consideration plus up to $95 million in contingent payments to accelerate speed-to-market for formulated supplements.
Acquired Link Biosciences to serve as a formulation and manufacturing engine for personalized powder-based supplements.
Identified China as a long-term opportunity despite current underpenetration, with plans to integrate Greater China leaders into global training events.
Factored preliminary estimates of higher oil prices into 2026 guidance, though management intends to absorb these costs as they are not currently considered material to the year, rather than raising consumer prices.
Story Continues
Q&A Session Highlights Protocol platform distributor behaviors and revenue expectations
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Management clarified that Protocol is currently in a beta phase to refine features based on distributor feedback across different regions and business models.
Confirmed that no direct revenue from Protocol or Vionic has been factored into the current 2026 financial forecast, representing potential upside.
The platform is designed to move the business from transactional to transformational by integrating wearables and biomarker data.
India growth sustainability and global pricing strategy
Expects momentum in India to continue beyond the September GST annualization, though year-over-year growth rates will likely moderate.
Management is running tests in other markets to see if price modifications or commission structure changes can stimulate volume growth similar to the India experience.
China market recovery and distributor leadership trends
China currently represents approximately 4% of sales and does not meaningfully contribute to profit; management is waiting for results before forecasting a turnaround.
For the first time, approximately 500 leaders from Greater China are participating in international Extravaganza events to build cross-border business momentum.
Subscription model adoption and e-commerce integration
Early data from the new DS Commerce platform shows positive uptake for product subscriptions, a first for the company’s history.
The Vionic launch in Europe will specifically feature a subscription-based personalized vitamin and mineral complex.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.